- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half of 2022 -
- Ended second quarter 2022 with cash, cash equivalents, and investments of $429.4; Expected cash runway into 2025 -
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2022.
We are excited about our recent IND submission for our lead candidate, CNTY-101, and pending FDA clearance, are looking forward to initiating the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma, said Lalo Flores, Chief Executive Officer, Century Therapeutics. We continue to make steady progress in building a best-in-class allogeneic cell therapy platform and achieved a key milestone this quarter in establishing the iNK 3.0 Common Progenitor, which we believe will accelerate new candidate selection. Additionally, we look forward to providing updates on our gamma delta iT platform and other program advancements in the coming months.
Business Highlights
The Company
preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, during a poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting held on May 16-19, 2022 in Washington, D.C. A copy of the presentation is available in the Posters section of Centurys website. During a Research and Development Event in June, Centurys management team discussed CNTY-103, the Companys first solid tumor candidate for glioblastoma, the establishment of the Common Progenitor iNK 3.0, and progress on the Companys next-generation iPSC-based cell therapy platform. Century expects to submit an Investigational New Drug (IND) application for CNTY-103 in 2024. The Companys current Good Manufacturing Practice (cGMP) manufacturing facility in Branchburg, New Jersey is operational and undergoing qualification.Century was added to the Russell Microcap Index in June 2022.
Subsequent Events and Upcoming Milestones
Following the recent submission of the IND application for CNTY-101, the Company remains on track to initiate its Phase 1 ELiPSE-1 clinical trial in the second half of 2022, subject to U.S. Food and Drug Administration (FDA) clearance of the application. ELiPSE-1 will assess CNTY-101 in patients with relapsed/refractory CD19 positive aggressive lymphoma or indolent lymphoma after at least two prior lines of therapy, including patients who have received prior CAR-T cell therapy.
Second Quarter 2022 Financial Results
Cash Position:Cash, cash equivalents, and investments were $429.4 million as of June 30, 2022, as compared to $358.8 million as of December 31, 2021. Net cash provided by operations was $61.2 million for the six months ended June 30, 2022 (which includes deferred revenue from the Bristol-Myers Squibb (BMS) collaboration of $120.7M) compared to net cash used in operations of $40.7 million for the six months ended June 30, 2021.Collaboration Revenue: Collaboration revenue was $1.4 million for the three months ended June 30, 2022, generated through the Companys collaboration, option and license agreement with BMS.Research and Development (R&D) expenses: R&D expenses were $24.5 million for the three months ended June 30, 2022, compared to $18.9 million for the same period in 2021. The increase in R&D expenses was primarily due to an increase in personnel expenses related to increased headcount to expand the Companys R&D capabilities, costs for pre-clinical studies, costs for laboratory supplies and facility costs, offset by a decrease in collaboration expenses with FUJIFILM Cellular Dynamics, Inc. (FCDI) as the scope of work with FCDI has narrowed down to primarily manufacturing CNTY-101 clinical supply. General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the three months ended June 30, 2022, compared to $4.1 million for the same period in 2021. The increase was primarily due to an increase in employee headcount, an increase in directors and officers insurance expense and an increase in the Companys professional fees as a result of expanded operations to support the Companys infrastructure as well as additional costs to operate as a public company, and increased information technology and facility costs. Net loss: Net loss was $31.0 million for the three months ended June 30, 2022, compared to $23.3 million for the same period in 2021.
Financial Guidance
The Company expects full year GAAP Operating Expenses to be between $155 million and $165 million including non-cash stock-based compensation expense of $10 million to $15 million. The Company expects its cash, cash equivalents, and investments will support operations into 2025.
About Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash, financial resources, and estimated expenses, our clinical development plans and timelines, and the development of our U.S. manufacturing facility are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as may, might, will, should, expect, plan, aim, seek, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, forecast, potential or continue or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the Risk Factors section of our most recent filings with the Securities and Exchange Commission and available at http://www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Company: Elizabeth Krutoholow investor.relations@centurytx.com
Investors: Melissa Forst/Maghan Meyers century@argotpartners.com
Media: Joshua R. Mansbach century@argotpartners.com
Go here to read the rest:
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - KULR-TV
- 2013 New Jersey Stem Cell Research Symposium [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Stem Cells and Cloning - New Jersey Right to Life | Prolife [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Regenexx Stem Cell Procedures - New York and New Jersey ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Wise Young, M.D., Ph.D., Announced as 12th New Jersey Symposium on Biomaterials Science Dinner Speaker [Last Updated On: September 4th, 2014] [Originally Added On: September 4th, 2014]
- Stem cell medicine - Worldnews.com [Last Updated On: September 6th, 2014] [Originally Added On: September 6th, 2014]
- Stem Cell Therapy Spine and Joint Bergen County New Jersey [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Sarah heads to Russia in latest battle in war on MS [Last Updated On: October 5th, 2014] [Originally Added On: October 5th, 2014]
- Frequently Asked Questions [FAQs] - Stem Cell Therapy New ... [Last Updated On: October 27th, 2014] [Originally Added On: October 27th, 2014]
- Targeting cancer stem cells: a new therapy to cure cancer ... [Last Updated On: October 29th, 2014] [Originally Added On: October 29th, 2014]
- Dynamic Imaging System Nets Yale Scientist the 2014 STEM CELLS Young Investigator Award [Last Updated On: December 4th, 2014] [Originally Added On: December 4th, 2014]
- A Few Cells Could Prevent Bone Marrow Transplant Infections [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- Stem Cells from Placenta Show Promise for Treating Heart Failure [Last Updated On: February 12th, 2015] [Originally Added On: February 12th, 2015]
- New Jersey Commission Science and Technology Grants - Stem ... [Last Updated On: February 13th, 2015] [Originally Added On: February 13th, 2015]
- FDA Expands Indication for REVLIMID (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly ... [Last Updated On: February 18th, 2015] [Originally Added On: February 18th, 2015]
- ADDING MULTIMEDIA FDA Expands Indication for REVLIMID (Lenalidomide) in Combination with Dexamethasone to Include ... [Last Updated On: February 19th, 2015] [Originally Added On: February 19th, 2015]
- EAT A PEACH | Beneficial Bacteria [Last Updated On: April 7th, 2015] [Originally Added On: April 7th, 2015]
- Orthopedic Stem Cell Solutions at the Spine & Pain Center ... [Last Updated On: May 8th, 2015] [Originally Added On: May 8th, 2015]
- Research at Rutgers | Rutgers University [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Research Overview | Rutgers Cancer Institute of New Jersey [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- The New Jersey Cord Blood Bank (NJCBB) [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- NJMS Stem Cells - Rutgers New Jersey Medical School [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- New York and New Jersey - Stem Cell Therapy & Platelet ... [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- New results on stem cells ageing - CODIF Recherche et ... [Last Updated On: August 1st, 2016] [Originally Added On: August 1st, 2016]
- Basic Science FAQs - Stem Cell Institute of New Jersey [Last Updated On: October 29th, 2016] [Originally Added On: October 29th, 2016]
- Stem Cell - New Jersey Catholic Conference - Trenton, NJ [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- Non-Surgical - The New Jersey Orthopaedic Institute [Last Updated On: November 27th, 2016] [Originally Added On: November 27th, 2016]
- Blood Drive To Honor 2 1/2-year-old Brain Tumor Patient, 4-year-old Lymphoma Patient - TAPinto.net [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- WCT selected to conduct Ph III NurOwn Trial in ALS - OutSourcing-Pharma.com [Last Updated On: July 6th, 2017] [Originally Added On: July 6th, 2017]
- FDA OKs Pfizer drug for rare, fast-killing type of leukemia - New Jersey Herald [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform - TASS [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Stem Cell Center Of NJ - New Jersey Stem Cell Therapy [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Blood Donations Needed During Labor Day Holiday Season - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Taconic, Silverstein to build 150000 s/f life science research center - Real Estate Weekly [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Blood Donations Needed During Labor Day Holiday Season - TAPinto - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Lab-made "mini organs" helping doctors treat cystic fibrosis - New Jersey Herald [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- Blood Donations Needed Pre and Post Labor Day Holiday - East ... - TAPinto.net [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- National Stem Cell Centers | Stem Cell Therapy in New York ... [Last Updated On: June 20th, 2018] [Originally Added On: June 20th, 2018]
- Regenexx Stem Cell Procedures - New York and New Jersey Metro [Last Updated On: July 15th, 2018] [Originally Added On: July 15th, 2018]
- New York & New Jersey - Stem Cell Therapy & Platelet Rich ... [Last Updated On: July 24th, 2018] [Originally Added On: July 24th, 2018]
- FAQ - Stem Cell Center Of NJ - New Jersey Stem Cell Therapy [Last Updated On: July 29th, 2018] [Originally Added On: July 29th, 2018]
- New Jersey Regenerative Medicine Stem Cell and PRP ... [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- Stem Cells and Cloning | New Jersey Right to Life [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- Cord Blood Storage, NY and NJ | Community Blood Services [Last Updated On: September 20th, 2018] [Originally Added On: September 20th, 2018]
- Stem Cell Therapy in New Jersey | National Stem Cell Centers [Last Updated On: November 13th, 2018] [Originally Added On: November 13th, 2018]
- Do Stem Cells Really Work? - New Jersey Stem Cell Therapy [Last Updated On: December 19th, 2018] [Originally Added On: December 19th, 2018]
- Obtain Stem Cell Therapy in New Jersey - Stem Cell Miami [Last Updated On: February 23rd, 2019] [Originally Added On: February 23rd, 2019]
- PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly [Last Updated On: October 14th, 2019] [Originally Added On: October 14th, 2019]
- Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- On Stage: Allegaeon ready to rock Philly - The Unionville Times [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly [Last Updated On: November 2nd, 2019] [Originally Added On: November 2nd, 2019]
- PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Live Cell Imaging Consumables Market Evolving to a Next-Generation Strategy with New Partnerships, Technologies and Targets by 2023 key players LCC... [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... [Last Updated On: November 6th, 2019] [Originally Added On: November 6th, 2019]
- Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald [Last Updated On: November 28th, 2019] [Originally Added On: November 28th, 2019]
- Weekly pick of Neuroscience news from around the world - Brain Tumour Research [Last Updated On: November 30th, 2019] [Originally Added On: November 30th, 2019]
- Stemming the Tide Confronting Anti-Semitism in the 21st Century - The Times of Israel [Last Updated On: January 5th, 2020] [Originally Added On: January 5th, 2020]
- Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Horizon to provide access to novel base editing technology - SelectScience [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance [Last Updated On: January 15th, 2020] [Originally Added On: January 15th, 2020]
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 [Last Updated On: January 20th, 2020] [Originally Added On: January 20th, 2020]
- TV Guy: A return to history with Auschwitz Untold - New Jersey Herald [Last Updated On: January 27th, 2020] [Originally Added On: January 27th, 2020]
- Musicians and community coming together in Asbury Park to help Point Pleasant 3-year old - Asbury Park Press [Last Updated On: February 12th, 2020] [Originally Added On: February 12th, 2020]
- Are stem cells really the key to making humans live longer? - Wired.co.uk [Last Updated On: February 16th, 2020] [Originally Added On: February 16th, 2020]
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today [Last Updated On: March 4th, 2020] [Originally Added On: March 4th, 2020]
- CO2 Incubators Market Update: Uncover the Business Strategies of Leaders & Laggards of the Market - 3rd Watch News [Last Updated On: March 6th, 2020] [Originally Added On: March 6th, 2020]
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... [Last Updated On: May 6th, 2020] [Originally Added On: May 6th, 2020]
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... [Last Updated On: May 13th, 2020] [Originally Added On: May 13th, 2020]
- CO2 Incubators Market is Expected to Witness a Steady Growth by 2025 - Farmers Ledger [Last Updated On: June 4th, 2020] [Originally Added On: June 4th, 2020]